Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martha Nason

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Plos One|March 31, 2010
Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferretSrinivas S Rao, Wing-Pui Kong, Chih-Jen Wei, et al.
Vaccine|December 3, 2014
Use of placebos in Phase 1 preventive HIV vaccine clinical trialsYunda Huang, Shelly T Karuna, Holly Janes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2019
Adaptive Viral Load Monitoring Frequency to Facilitate Differentiated Care: A Modeling Study From Rakai, UgandaVictor Ssempijja, Martha Nason, Gertrude Nakigozi, et al.
Journal of Virology|September 28, 2007
A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infectionChristof Geldmacher, Clive Gray, Martha Nason, et al.
The Journal of Infectious Diseases|December 23, 2016
Assessment and Optimization of the GeneXpert Diagnostic Platform for Detection of Ebola Virus RNA in Seminal FluidJames Pettitt, Elizabeth Higgs, Mosoka Fallah, et al.
Journal of Virology|January 20, 2012
HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopesNicole A Doria-Rose, Mark K Louder, Zhongjia Yang, et al.
The Journal of Infectious Diseases|February 26, 2015
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure ProphylaxisOliver Laeyendecker, Andrew D Redd, Martha Nason, et al.
Nature Communications|June 26, 2020
Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodiesDavid A Garber, Debra R Adams, Patricia Guenthner, et al.
Journal of Immunotoxicology|October 3, 2008
Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene insertsRebecca L Sheets, Judith Stein, Robert T Bailer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 19, 2024
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 VaccineDean Follmann, Allyson Mateja, Michael P Fay, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Plos One|March 31, 2010
Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferretSrinivas S Rao, Wing-Pui Kong, Chih-Jen Wei, et al.
Vaccine|December 3, 2014
Use of placebos in Phase 1 preventive HIV vaccine clinical trialsYunda Huang, Shelly T Karuna, Holly Janes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2019
Adaptive Viral Load Monitoring Frequency to Facilitate Differentiated Care: A Modeling Study From Rakai, UgandaVictor Ssempijja, Martha Nason, Gertrude Nakigozi, et al.
Journal of Virology|September 28, 2007
A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infectionChristof Geldmacher, Clive Gray, Martha Nason, et al.
The Journal of Infectious Diseases|December 23, 2016
Assessment and Optimization of the GeneXpert Diagnostic Platform for Detection of Ebola Virus RNA in Seminal FluidJames Pettitt, Elizabeth Higgs, Mosoka Fallah, et al.
Journal of Virology|January 20, 2012
HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopesNicole A Doria-Rose, Mark K Louder, Zhongjia Yang, et al.
The Journal of Infectious Diseases|February 26, 2015
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure ProphylaxisOliver Laeyendecker, Andrew D Redd, Martha Nason, et al.
Nature Communications|June 26, 2020
Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodiesDavid A Garber, Debra R Adams, Patricia Guenthner, et al.
Journal of Immunotoxicology|October 3, 2008
Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene insertsRebecca L Sheets, Judith Stein, Robert T Bailer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 19, 2024
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 VaccineDean Follmann, Allyson Mateja, Michael P Fay, et al.
Pageof 8